Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India · Delayed Price · Currency is INR 58.80
-0.82 (-1.38%)
Nov 11, 2026, 2:53 PM IST
NSE:KREBSBIO Revenue
Krebs Biochemicals & Industries had revenue of 57.90M INR in the quarter ending September 30, 2026, with 38.94% growth. This brings the company's total for the last twelve months to 268.57M, down -1.32% year-over-year. In the fiscal year ending March 31, 2026, Krebs Biochemicals & Industries had annual revenue of 237.32M, down -45.21%.
Revenue (ttm)
268.57M
Revenue Growth
-1.32%
P/S Ratio
4.71
Revenue / Employee
1.89M
Employees
142
Market Cap
1.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 237.32M | -195.80M | -45.21% |
| Mar 31, 2025 | 433.12M | -71.10M | -14.10% |
| Mar 31, 2024 | 504.22M | -17.13M | -3.29% |
| Mar 31, 2023 | 521.34M | -75.69M | -12.68% |
| Mar 31, 2022 | 597.03M | 70.20M | 13.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.91B |
| Valiant Laboratories | 3.76B |
| Amanta Healthcare | 3.04B |
| Balaxi Pharmaceuticals | 2.80B |
| Alpa Laboratories | 1.11B |
| Vaishali Pharma | 1.08B |
| Par Drugs and Chemicals | 1.08B |
| Brooks Laboratories | 795.39M |
Krebs Biochemicals & Industries News
- 1 year ago - Krebs Biochemicals & Industries halts production following order from Andhra Pradesh Pollution Control Board - Business Upturn